Stock 600420 SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 2024-12-05 		5-day change 1st Jan Change
12.06 CNY -0.08% Intraday chart for Shanghai Shyndec Pharmaceutical Co., Ltd. +0.50% +23.19%
Dec. 03 Shanghai Shyndec Pharmaceutical Gets Drug Registration for Eye Drops MT
Nov. 27 Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shanghai Shyndec Pharmaceutical Gets Drug Registration for Eye Drops
Dec. 03
 MT
Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection
Nov. 27
 MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
Oct. 28
 CI
China Approves Shyndec Pharmaceutical's Listing Application for Epilepsy Drug Ingredient
Sep. 05
 MT
Shyndec Pharmaceutical Gets Nod to Add Specification to Pravastatin Sodium Tablets
Aug. 30
 MT
Shyndec Pharmaceutical's H1 Profit Soars 108%, Operating Income Slips 8%
Aug. 28
 MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024
Aug. 27
 CI
Shanghai Shyndec Pharmaceutical Antibiotic Drug Passes Drug Consistency Evaluation
Aug. 12
 MT
Shanghai Shyndec Pharmaceutical's Chest Pain Drug Passes China's Drug Evaluations
Jul. 31
 MT
Shyndec Pharmaceutical's Unit Gets Nod to Amend Lipoic Acid Injection's Specification
Jul. 19
 MT
Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection
Jul. 12
 MT
Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%
Jul. 09
 MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 29
 CI
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets
Apr. 16
 MT
China stocks rise after new guidelines; HK shares drop
Apr. 15
 RE
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator
Mar. 27
 MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine
Mar. 07
 MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation
Feb. 20
 MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation
Feb. 20
 MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Jan. 25
 CI
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid
Nov. 08
 MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation
Nov. 07
 MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-26
 CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing
23-09-19
 MT
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient
23-09-14
 MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600420 Stock
  4. News Shanghai Shyndec Pharmaceutical Co., Ltd.
  5. Highlights